ERBB2 and neoplasm: The HSP90 peptides were able to stimulate an anti-HSP90 response in HER2+ tumors in vivo with an increased CD8+ T cell: Treg ratio and decreased HER2+ tumor volumes [198], demonstrating another promising strategy to treat trastuzumab-resistant HER2+ BC.